TerminatedPhase 4NCT02443545
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
Studying Dietary iron overload disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ApoPharma
- Principal Investigator
- Janet Kwiatkowski, MDChildren's Hospital of Philadelphia
- Intervention
- Deferiprone(drug)
- Enrollment
- 134 enrolled
- Eligibility
- 3 years · All sexes
- Timeline
- 2015 – 2019
Study locations (13)
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- The Children's Hospital of Philadephia, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Hospital for Sick Kids, Toronto, Ontario, Canada
- Zagazig University, Alexandria, Egypt
- Ain Shams University, Cairo, Egypt
- Cairo University, Cairo, Egypt
- Pediatric Hospital of Cairo University, Cairo, Egypt
- Asser Central Hospital, Abhā, Saudi Arabia
- Barts and The London, London, United Kingdom
- Evelina Children's Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02443545 on ClinicalTrials.govOther trials for Dietary iron overload disease
Additional recruiting or active studies for the same condition.